- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05318898
Effect of Dietary Protein on the Regulation of Exosome MicroRNA Expression in Patients with Insulin Resistance.
Effect of Dietary Protein on the Regulation of Exosome MicroRNA Expression in Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will evaluate the effect of 2 dietary interventions on the regulation of plasma exosome microRNA expression in patients with insulin resistance.
STUDY PROGRAM
The study will consist of 3 visits
Planned (selection of participants)
- Participants will be invited through advertisements.
- Participants will be corroborated to ensure that they meet the criteria for selection.
- If they are candidates for the protocol, participants will be provided with the letter of consent to read carefully and any doubts that may arise will be resolved. Participants will be informed about the characteristics of the study as well as the expected risks and benefits. If they agree, the participant will be asked to sign the consent form.
- Anthropometric measurements such as weight, height, blood pressure and body composition will be determined by means of bioelectrical impedance.
- A 24-hour reminder of food consumption will be made.
- A whole blood sample will be taken for glucose and insulin determination, in order to determine the HOMA-Insulin Resistance index.
Once the insulin resistance patients are identified (HOMA- Insulin Resistance ≥ 2.5) the study will begin and participants will be randomized into two intervention groups.
Visit 1 (baseline)
- A medical and nutritional assessment will be performed.
- The physical activity questionnaire (IPAQ long version) will be administered and participants will be advised not to change their physical activity.
- Anthropometric and blood pressure measurements will be taken.
- Oral glucose tolerance test will be performed for 2 hours after a 12-hour fast to determine the area under the insulin and glucose curve and determination of insulinemic and glycemic indices.
- A blood sample will be obtained to determine plasma exosome microRNA expression and C-reactive protein as a confounding variable for concurrent infection.
- The patient will be assigned to an intervention group (vegetable protein vs. animal protein) by block randomization.
- The participants will continue their usual diet, And the consumption of animal protein or the consumption of vegetable protein will be recommended, according to the assigned group. They will be given and explained a list of foods that provide proteins of animal and vegetable origin, which they could integrate into their usual diet, these lists will indicate which foods to consume and which not to consume, according to the intervention group to which they were assigned.
9. They will be given a logbook to write down their daily food consumption and they will be taught how to fill it out.
10. An online questionnaire will be explained how to fill out every third day to detect the consumption of recommended and non-recommended foods from the list provided, according to the assigned group.
11. They will be given a pantry with foods rich in protein only (animal protein vs. vegetable protein) according to the assigned group (explained in the section on pantries).
Visit 2 (intermediate)
- Consumption logs will be collected.
- The weekly pantry will be delivered
- Clarification of doubts
Visit 3 (final)
- A medical and nutritional assessment will be performed. 2.
- The physical activity questionnaire (IPAQ long version) will be completed.
- Anthropometric and blood pressure measurements will be performed.
- Oral glucose tolerance test will be performed for 2 hours after a 12 hour fast to determine the area under the insulin and glucose curve and determination of insulinemic and glycemic indices.
- A blood sample will be obtained to determine plasma exosome microRNA expression and C-reactive protein as a confounding variable for concurrent infection.
- Body temperature will be determined and if female, the date of last menstrual period will be questioned as a confounding variable.
- The food log will be collected.
- Clarification of doubts and thanks will be given for their participation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 14060
- Martha Guevara Cruz
-
-
México
-
Mexico City, México, Mexico, 14080
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (men and women) between the ages of 18 and 60.
- Patients with obesity (BMI ≥ 30 and ≤ 50 kg / m2) and with insulin resistance (HOMA - Insulin Resistance Index ≥ 2.5).
- Signature of letter of consent
Exclusion Criteria:
- Patients with any type of diabetes.
- Patients with kidney disease diagnosed by a medical or with creatinine> 1.3 mg / dL for men and > 1.1 mg / dL for women and / or blood urea nitrogen > 20 mg / dL.
- Patients with acquired diseases that produce obesity and diabetes secondarily.
- Patients who have suffered a cardiovascular event.
- Patients with weight loss > 3 kg in the last 3 months.
- Patients with any catabolic diseases.
- Gravidity status
- Positive smoking and alcoholism
- Treatment with any medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Regular diet with vegetable protein
Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetable protein sources.
|
Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
|
|
Active Comparator: Regular diet with animal protein
Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
|
Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the expression profile of microRNAs from exosomes with real -time quantitative polymerase chain reaction in fold change
Time Frame: 4 weeks
|
Fold change in the expression profile of microRNAs from exosomes after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) with real -time quantitative polymerase chain reaction
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on HOMA index
Time Frame: 4 weeks
|
Change in the HOMA index after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal).
|
4 weeks
|
|
Change in body weight in kg
Time Frame: 4 weeks
|
Change in the body weight in kg after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) using a standard calibrated electronic balance.
|
4 weeks
|
|
Change in biochemical parameters in mg/dL
Time Frame: 4 weeks
|
Change the biochemical parameters in mg/dL ( glucose, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol) after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) analysed by an enzymatic colorimetric method using the Cobas C111 analyser (Roche Diagnostic.
Indianapolis.
IN).
|
4 weeks
|
|
Change in body composition in percentage
Time Frame: 4 weeks
|
Change in the body composition in percentage after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) by multifrequency bioimpedance analysis.
|
4 weeks
|
|
Change in C Reactive Protein in mg/L
Time Frame: 4 weeks
|
Change in C Reactive Protein in mg/L after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) analysed by an enzymatic colorimetric method using the Cobas C111 analyser (Roche Diagnostic.
Indianapolis.
IN).
|
4 weeks
|
|
Amino acid profile in mmol/L
Time Frame: 4 weeks
|
Change in amino acid profile in mmol/L after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) determinated by High performance liquid chromatography
|
4 weeks
|
|
Change in the area under curve of glucose in mg/dL per 2 hours
Time Frame: 4 weeks
|
Change in the area under curve of glucose in mg/dL per 2 hours after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal).
|
4 weeks
|
|
Change in the area under curve of insulin in microIU/mL per 2 hours
Time Frame: 4 weeks
|
Change in the area under curve of insulin in micro IU/mL per 2 hours after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal).
|
4 weeks
|
|
Change in the waist circumference in centimeters
Time Frame: 4 weeks
|
Change in the waist circumference in centimeters after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) using a flexible tape measure.
|
4 weeks
|
|
Change in the blood pressure in mmHg
Time Frame: 4 weeks
|
Change in the blood pressure in mmHg after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal).
|
4 weeks
|
|
Change in the Malondialdehyde in micromol/L
Time Frame: 4 weeks
|
Change in the Malondialdehyde in micromol/L after 4 weeks of usual diet with consumption of different protein sources (vegetable vs. animal) measured by ELISA
|
4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martha Guevara-Cruz, Doctor, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Publications and helpful links
General Publications
- Lasser C. Mapping Extracellular RNA Sheds Lights on Distinct Carriers. Cell. 2019 Apr 4;177(2):228-230. doi: 10.1016/j.cell.2019.03.027.
- Mori MA, Ludwig RG, Garcia-Martin R, Brandao BB, Kahn CR. Extracellular miRNAs: From Biomarkers to Mediators of Physiology and Disease. Cell Metab. 2019 Oct 1;30(4):656-673. doi: 10.1016/j.cmet.2019.07.011. Epub 2019 Aug 22.
- Safdar A, Tarnopolsky MA. Exosomes as Mediators of the Systemic Adaptations to Endurance Exercise. Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):a029827. doi: 10.1101/cshperspect.a029827.
- Huang Y, Yan Y, Xv W, Qian G, Li C, Zou H, Li Y. A New Insight into the Roles of MiRNAs in Metabolic Syndrome. Biomed Res Int. 2018 Dec 17;2018:7372636. doi: 10.1155/2018/7372636. eCollection 2018.
- Castano C, Kalko S, Novials A, Parrizas M. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12158-12163. doi: 10.1073/pnas.1808855115. Epub 2018 Nov 14.
- Jimenez-Lucena R, Alcala-Diaz JF, Roncero-Ramos I, Lopez-Moreno J, Camargo A, Gomez-Delgado F, Quintana-Navarro GM, Vals-Delgado C, Rodriguez-Cantalejo F, Luque RM, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Rangel-Zuniga OA, Lopez-Miranda J. MiRNAs profile as biomarkers of nutritional therapy for the prevention of type 2 diabetes mellitus: From the CORDIOPREV study. Clin Nutr. 2021 Mar;40(3):1028-1038. doi: 10.1016/j.clnu.2020.06.035. Epub 2020 Jul 15.
- Min KH, Yang WM, Lee W. Saturated fatty acids-induced miR-424-5p aggravates insulin resistance via targeting insulin receptor in hepatocytes. Biochem Biophys Res Commun. 2018 Sep 10;503(3):1587-1593. doi: 10.1016/j.bbrc.2018.07.084. Epub 2018 Jul 20.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3986-22-22-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
German Diabetes CenterYale UniversityRecruiting
-
Paloma Almeda-ValdésCompleted
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
Société des Produits Nestlé (SPN)CompletedInsulin Sensitivity/ResistanceSwitzerland
-
University of CopenhagenNovo Nordisk A/S; Queen Mary University of London; University of SydneyNot yet recruitingInsulin Sensitivity/Resistance | Metabolic HealthDenmark
-
Assiut UniversityCompleted
-
University of Colorado, DenverRecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | TransgenderismUnited States
Clinical Trials on Vegetal protein
-
Ahmad Mustafa Mohamed MetwalleyIbn Sina HospitalCompleted
-
SanofiCompleted
-
Medical University of ViennaCompleted
-
University of ArizonaCompletedAsthma | WheezingUnited States
-
University Hospital, RouenCompletedMetabolic Syndrome | Essential HypertensionFrance
-
Örebro University, SwedenRecruitingIleostomy - StomaSweden
-
VitaKey Inc.Biofortis Clinical Research, Inc.; United States Department of Defense (DOD)Not yet recruiting
-
University of Illinois at Urbana-ChampaignNational Cattlemen's Beef AssociationCompletedDietary Habits | Muscle Protein Synthesis | Meal FrequencyUnited States